<DOC>
	<DOCNO>NCT01820559</DOCNO>
	<brief_summary>This multinational , randomised , double-blind , placebo-controlled , parallel-group study evaluate efficacy , safety , tolerability multiple dos ESL prophylactic treatment subject migraine without aura . Subjects randomise 1:1:1 ratio receive placebo , ESL 800 mg/day daily ( QD ) , ESL 1200 mg/day QD .</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate Preventive Therapy Subjects With Migraine</brief_title>
	<detailed_description>The study consist Screening Period 2 4 week , 4-week placebo Baseline Period , 2-week Titration Period , 12-week Maintenance Period , 4-week Follow-up Period . During entire study subject diary document occurrence , duration , intensity headache , occurrence aura nature , well relate symptom , use study medication acute medication .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Women men , 18 year age older ( accord Amendment # 1 Czech Republic [ 24 Mar 2009 ] : 18 65 year age ) . Diagnosis ( establish prior 50 year age ) migraine headache least 1 year , welldocumented history migraine headache without aura accord criterion IHS ( see Section 3.5.6.1 ) least 3 month ( accord Amendment # 1 Czech Republic [ 24 Mar 2009 ] : least 3 month least 3 migraine attack per month 3 month ) . At least 2 ( accord Amendment # 1 Czech Republic [ 24 Mar 2009 ] : least 3 ) ( 10 ) welldefined migraine headache attack per month , least 24 h freedom headache symptoms migraine attack . Able distinguish migraine headache attack type common headache ( tensiontype headache , sinusrelated headache , etc. ) . Not take prophylactic migraine therapy least 2 week prior Baseline Visit ( V2 ) . Flunarizine discontinue least 4 week prior V2 . Able willing provide write informed consent participate study opportunity review Subject Information Sheet Informed Consent Form ( ICF ) . Able willing comply study requirement , judgment investigator . Women surgically sterile ( i.e . bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , least 2 year postmenopausal , childbearing potential , sexually abstinent agree use medically acceptable nonhormonal method contraception ( see Section 3.3.3 ) . ( According Amendment # 1 Czech Republic [ 24 Mar 2009 ] : Women sexually abstinent agree use doublebarrier method contraception . Hormonal contraceptives acceptable contraceptive method study . However , intake forbidden throughout study . ) A know hypersensitivity ESL carboxamide derivative ( e.g . oxcarbazepine , carbamazepine ) , excipients . Suspected confirmed medicationoveruse headache . More 14 headache day ( migraine headache type ) per month either 2 month prior screen . Consistent recurrent frequent headache ( i.e . ≥6 headache day month ) migraine headache . Unable discontinue medication primarily use migraine prophylaxis commonly use indication ( tricyclic agent , divalproic acid , topiramate , etc. ) . A subject receive beta blocker calcium channel blocker therapy reason migraine prophylaxis eligible inclusion , provide his/her dose regimen stable ≥2 month expect change course study . Using prohibit concomitant medication ( see Section 3.5.5.2 ) . A white blood cell ( WBC ) count &lt; 2.5 * 109/L , neutrophil count &lt; 1.5 * 109/L , sodium &lt; 125 mmol/L , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥2 time upper limit normal V1 ( Screening Visit ) , clinically relevant laboratory abnormality , investigator 's opinion , could compromise subject 's safety . A creatinine clearance lower 60 mL/min screening . A second thirddegree atrioventricular blockade correct pacemaker clinically significant abnormality 12lead electrocardiogram ( ECG ) determine investigator . Pregnant nursing woman . A history chronic alcohol drug abuse addiction within last 2 year . A severe hepatic , renal , respiratory , haematological , immunologic illness , unstable cardiovascular disease , medical psychiatric condition , judgment investigator , make subject inappropriate entry study . Received investigational drug ( medical device ) within 3 month screen currently participate another study investigational drug ( medical device ) . An employee investigator study centre , direct involvement propose study study direction investigator study centre , family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>migraine ; ESL ; eslicarbazepine acetate</keyword>
</DOC>